Search
Idebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalDue to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients [L885]. … It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.
Cefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie.
Coal tar
go.drugbank.com/drugs/DB11082ApprovedCoal tar is among the by-products when coal is carbonized to make coke or gasified to make coal gas. … It has been indicated for local relief of itching, dryness, and irritation caused by psoriasis, seborrhea and eczema.
Human interferon omega-1
go.drugbank.com/drugs/DB05472InvestigationalThere are multiple routes for administration of omega interferon: injection, an implantable subcutaneous drug delivery system, and an oral formulation. … It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering.
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Erythromycin
go.drugbank.com/drugs/DB00199ApprovedInvestigationalVet approved[L5245] Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. … Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational[A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical … [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605]
Elapegademase
go.drugbank.com/drugs/DB14712Approved[F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]
CY301
go.drugbank.com/drugs/DB06382ExperimentalCY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.
Etoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawn[T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]